Business Wire

Optiv Security Announces Key Executive Appointments in Europe Aligned to Global Services Expansion and International Growth Strategy

Jaa

Optiv Security, the world’s leading security solutions integrator, today announced it has named Nigel Gilhespy as European services director and Rob Lay as director of solutions architecture in Europe, two key appointments that support the company’s global services expansion and international growth strategy. Gilhespy is focused on developing and expanding Optiv’s security services capabilities in Europe to meet the evolving cyber security needs of locally-based organisations and global clients. Lay is responsible for working with clients to help them select the right technology and solutions to rationalize infrastructure, optimise operations, and meet unique business objectives.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180726005096/en/

Nigel Gilhespy. (Photo Business Wire)

Nigel Gilhespy. (Photo Business Wire)

“Chief information security officers and other technology executives in Europe – and around the world – are facing unprecedented challenges,” said Simon Church, general manager and executive vice president, Europe. “Their adversaries are unrelenting, creative and effective. Their defences are complex, expensive and manpower-intensive. They have little, if any, empirical insight into how much money their organisations should be spending or on which areas that money should be spent. And, their ability to effectively measure and report on the security operation’s impact against corporate business goals make it difficult for them to gain a ‘seat at the table’ in the executive suite and the boardroom. The cyber security industry has gotten into this predicament largely due to a reactive approach, buying technologies based on latest trends and vulnerabilities rather than investing in the right people, processes and technologies to balance security and business needs.

“Optiv is uniquely positioned to help global clients improve the consistency and effectiveness of their security programs, and minimise cost. We are seeing solid momentum in Europe as clients embrace our ‘inside out’ risk-centric approach to security, where security investments are driven by corporate objectives rather than fear of external threats and vulnerabilities. I am extremely pleased to welcome Nigel and Rob to the Optiv team, and look forward to leveraging their business, technical and client service experience to help more public and private entities build sustainable risk-centric foundations for implementing proactive and measurable cyber security programs.”

Gilhespy brings to his role at Optiv more than 30 years of business, leadership and technical expertise, including building, running and growing world-class professional services and consulting organisations for top cyber security companies in EMEA. He was previously head of consulting and professional services EMEA for Palo Alto Networks, where he achieved 90 percent customer satisfaction and 100 percent year-over-year growth. Gilhespy also served as head of professional and consulting services, EMEA enterprise for Juniper Networks, where he managed global practices for security, mobility, SDN, core routing, and OSS, among others. In addition, Gilhespy has held leadership positions at IBM and Equinix.

Lay is an information security strategist and disruptive thinker with more than a decade of experience in information security consulting roles. He joined Optiv from Fujitsu’s UK&I where he led the pre-sales organisation. Lay previously served as senior information security consultant for Integralis, and as principle information security consultant after the company rebranded as NTT Com Security. In those roles, Lay was responsible for operational management, development and strategy of client-specific onsite security operations centers; and provided security operations consulting to major account clients, including designing, building, oversight, operations and ongoing optimisation and strategy.

Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: https://www.youtube.com/c/OptivInc
Blog: www.optiv.com/resources/blog
Newsletter: www.optiv.com/optiv-advisor

About Optiv Security
Optiv helps clients plan, build and run successful cyber security programs that achieve business objectives through our depth and breadth of cyber security offerings, extensive capabilities and proven expertise in cyber security strategy, managed security services, incident response, risk and compliance, security consulting, training and support, integration and architecture services, and security technology. Optiv maintains premium partnerships with more than 350 of the leading security technology manufacturers. For more information, visit www.optiv.com.

Contact information

Octopus Group for Optiv
Optiv@octopusgrp.com
or
Optiv Security
Susan Vaillancourt, 603-459-8906
susan.vaillancourt@optiv.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market17.10.2018 09:18Tiedote

Biogen (Nasdaq:BIIB) and Samsung Bioepis Co., Ltd. today announced the European launch of IMRALDI™ (adalimumab), a biosimilar referencing HUMIRA®. Starting today, IMRALDI™ will begin launching in major markets across Europe. The launch of IMRALDI™ marks a significant milestone for Biogen and Samsung Bioepis, as the adalimumab product is the third anti-TNF biosimilar developed by Samsung Bioepis to be commercialized by Biogen across Europe. BENEPALI™ (etanercept) and FLIXABI™ (infliximab) were approved in 2016, and have approximately 100,000 patients currently under treatment with more than 6 million doses administered across 25 and 14 countries, respectively.ii “We look forward to increasing patient access to this important medicine by leveraging our industry-leading position in the European anti-TNF market,” said Ian Henshaw, Head of Biogen’s Biosimilars Unit. “The launch of IMRALDI marks what we believe to be a landmark moment for Biogen and Samsung Bioepis and for European healthcar

Durabook Delivers World’s Toughest Semi-Rugged Computer17.10.2018 09:00Tiedote

Durabook, the global brand fully owned by Twinhead International Corporation, has today introduced the most durable semi-rugged computer ever created. The Durabook S14I greatly exceeds all existing devices in its class in both drop height and IP ratings. Built with 8th generation Intel® CPU and a wide selection of I/O options, the S14I is ideal for demanding working environments of public safety, government, military and field service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016006151/en/ Durabook S14I Features Class-Leading Drop Height and IP Ratings along with 8th Generation Intel CPU Power (Photo: Business Wire) “As the definition of the modern workplace expands, the line between what is office and what is field are often becoming blended” said Fred Kao, CEO of Twinhead. “So we are blending the line between what is a semi-rugged and what is a fully-rugged. Under the form factor of a traditional semi-rugged lapto

DIA Drives Debates and Solutions at the Crossroads of Healthcare17.10.2018 09:00Tiedote

DIA, founded as the Drug Information Association, announced three keynote speakers for the upcoming DIA Europe 2019 annual meeting: Dave deBronkart, ‘e-Patient Dave’; Hans Lehrach, Director at the Max Planck Institute for Molecular Genetics; and Kristel Van der Elst, CEO, The Global Foresight Group. The diversity of experience brought by these three leaders is reflective of the meeting mission to ensure industry, payers, patients, and regulators all have an equal voice in the debates advancing regulatory science and access to healthcare. These keynote speakers will join 300 speakers in more than 80 sessions, across seven thought leadership streams to drive collaborative answers in medicines development and access to healthcare. Highlights from sessions include Guido Rasi, Executive Director, EMA, will present first look strategies for 2021-2025 during the European Regulatory Town Hall and Niklas Hedberg, Chair EUnetHTA Executive Board, will feature case studies of Real World Evidence i

SailPoint’s Latest SaaS Release Makes Security and Compliance Accessible to All Enterprises17.10.2018 08:01Tiedote

SailPoint Technologies Holdings, Inc. (NYSE: SAIL), the leader in enterprise identity governance, unveiled a series of new innovations in IdentityNow, the industry’s most comprehensive SaaS identity governance platform. Enhancements have been made with an eye towards both closing security and compliance gaps and simplifying identity implementations for organizations who may not have dedicated identity teams and resources. New in IdentityNow is the Dynamic Discovery Engine, an innovation that allows users to easily and quickly create policies, access reviews, dashboards and reporting. As a result, IdentityNow customers are better able to address the mounting security and compliance challenges that all enterprises face today. “When we started our identity governance journey, a key requirement for us was the ability to automate identity processes where we could, while improving our audit and compliance track record,” said Michael Boucher, Sr. Director, Information Risk Management, FTD. “W

Ferring and Evotec Form Strategic Research Alliance in Reproductive Medicine and Women’s Health17.10.2018 08:00Tiedote

Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016005907/en/ Evotec will apply its drug discovery platform to design novel and efficacious treatments in partnership with Ferring. The multi-target, multi-year collaboration aims to deliver small molecule pre-clinical development (PDC) and investigational new drug (IND) ready candidates. As part of the alliance, Evotec is eligible for undisclosed research funding and milestones. “To achieve leadership in reproductive medicine and women’s health, we are expanding beyond our historical expertise in peptides and tackling molecular targets that are best addressed using small molecule therapeutics,” said Per Fal

IWBI Launches Global Network of Advisors for WELL Portfolio16.10.2018 21:00Tiedote

The International WELL Building Institute™ (IWBI™) today announced the formation of a global advisory to help shape and advance the implementation of the WELL Portfolio™ Pathway pilot, a new streamlined pathway for WELL Certification™ for multiple new or existing buildings and tenant spaces in a single portfolio. WELL Portfolio, announced this past month, is being released as part of the WELL v2™ pilot, the latest iteration of the WELL Building Standard™ (WELL™). It is part of a suite of enhancements to WELL that addresses growing demand across the building industry for a program that helps owners, developers and tenants streamline and scale health and wellness upgrades to their real estate assets. The advisory includes a collection of professionals, practitioners and experts across a range of industries and sectors, each serving a one-year term. “Since we launched WELL, we’ve seen an explosion of interest from global companies to bring the same health and wellness benefits across thei

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme